MARKET

GKOS

GKOS

Glaukos Corp
NYSE
113.27
+0.75
+0.67%
After Hours: 113.27 0 0.00% 16:49 02/09 EST
OPEN
112.63
PREV CLOSE
112.52
HIGH
113.51
LOW
110.39
VOLUME
538.82K
TURNOVER
--
52 WEEK HIGH
161.78
52 WEEK LOW
73.16
MARKET CAP
6.51B
P/E (TTM)
-73.0444
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GKOS last week (0202-0206)?
Weekly Report · 16h ago
How FDA Approval of Repeat iDose TR Use Will Impact Glaukos (GKOS) Investors
Simply Wall St · 6d ago
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards
Seeking Alpha · 6d ago
Assessing Glaukos (GKOS) Valuation After FDA Approval For Repeat iDose TR Use
Simply Wall St · 02/02 10:17
Weekly Report: what happened at GKOS last week (0126-0130)?
Weekly Report · 02/02 10:05
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS), Perspective Therapeutics (CATX) and Glaukos (GKOS)
TipRanks · 01/30 14:30
Glaukos assumed with an Outperform at William Blair
TipRanks · 01/30 12:16
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
Seeking Alpha · 01/30 03:30
More
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Webull offers Glaukos Corp stock information, including NYSE: GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.